NeuroSolutions Enters into a Collaboration Agreement with Gentronix
News Jun 08, 2006
Pursuant to the agreement both companies will seek to assess the genetic toxicology of NSL-105 by using GreenScreen, Gentronix’s commercially available yeast-based assay.
In particular, the assay’s specificity is demonstrated by the extremely low incidence of false positives compared to other available tests.
NeuroDiscovery Chairman, Dr Mark Treherne said, "We are delighted to collaborate with Gentronix and this agreement will provide us with a significant opportunity to accelerate the development of NSL-105 to build an in-depth pipeline of innovative products for the treatment of a variety of painful medical conditions."
"Recent forecasts predict a global market value for neuropathic pain treatments of over US$4 billion by 2007."
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Chili Pepper Derived Anti-Obesity Drug Shows Promise in Animal TrialsNews
A novel drug based on capsaicin, the compound that gives chili peppers their spicy burn, caused long term weight loss and improved metabolic health in mice eating a high fat diet.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019